CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of skin cancer.
  
  LEARNING OBJECTIVES

  • Recall long-term outcomes with traditional treatment approaches for localized or locally advanced cutaneous squamous cell carcinoma (cSCC), and recognize clinical and histologic features that increase the risk of recurrence after primary therapy.
  • Evaluate available research findings with immunotherapeutic agents as a component of neoadjuvant therapy for resectable cSCC in order to identify patients who may be appropriate candidates for this strategy.
  • Appreciate recently published Phase III data supporting the use of adjuvant anti-PD-1 antibody therapy after surgery and radiation therapy for patients with high-risk cSCC, and consider the potential clinical utility and practical application of this approach.
  • Use available clinical trial evidence to safely and effectively integrate immunotherapeutic approaches into the care of patients with advanced or metastatic cSCC.
  • Formulate a long-term plan for the management of locally advanced or metastatic basal cell carcinoma (BCC), incorporating targeted and immunotherapeutic strategies.
  • Recollect the rationale for and design of ongoing clinical trials evaluating novel agents and strategies for cSCC and BCC, and appropriately counsel patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: Research To Practice designates this enduring material for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Program: Research To Practice designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 3 (audio) and 2.5 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
  Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
  
  Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  To receive credit for an activity in this series, the participant should review the CME information, listen to or view the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation. Program location URLs are noted below:
  
  Audio Program: ResearchToPractice.com/NonmelanomaSkinThinkTank2025 and evaluation ResearchToPractice.com/NonmelanomaSkinThinkTank2025/CME.
  
  Video Program: ResearchToPractice.com/NonmelanomaSkinThinkTank2025/Video and evaluation ResearchToPractice.com/NonmelanomaSkinThinkTank2025/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of these activities. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Nikhil I Khushalani, MD
  Senior Member and Vice Chair
  Department of Cutaneous Oncology
  Moffitt Cancer Center
  Tampa, Florida
  
  Advisory Committees and Consulting Agreements: Bristol Myers Squibb, Castle Biosciences Incorporated, Immunocore, Instil Bio, IO Biotech, Iovance Biotherapeutics, Merck, Mural Oncology, MyCareGorithm, Nektar Therapeutics, Novartis, Regeneron Pharmaceuticals Inc, Replimune, Sun Pharmaceutical Industries Ltd; Contracted Research (All to Institution): Bristol Myers Squibb, Celgene Corporation, GSK, HUYABIO International, IDEAYA Biosciences, Merck, Modulation Therapeutics, Novartis, Regeneron Pharmaceuticals Inc, Replimune; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP, Incyte Corporation; Stock Options — Private Companies: Asensus Surgical; Stock Options/Stock — Public Companies: Bellicum Pharmaceuticals Inc.
  
  Soo J Park, MD
  Associate Professor of Medicine and Dermatology
  Division of Hematology/Oncology
  UC San Diego Moores Cancer Center
  San Diego, California
  
  Consulting Agreements: Regeneron Pharmaceuticals Inc, Sun Pharmaceutical Industries Ltd; Contracted Research: Bristol Myers Squibb; Data and Safety Monitoring Boards/Committees: Replimune.
  
  Vishal Anil Patel, MD
  Director of Cutaneous Oncology, GW Cancer Center
  Director of Dermatologic Surgery, GW Department of Dermatology
  Associate Professor of Dermatology and of Medicine (Oncology)
  George Washington University School of Medicine and Health Sciences
  Washington, DC
  
  Advisory Committees: Almirall, Biofrontera Inc, Regeneron Pharmaceuticals Inc, Sun Pharmaceutical Industries Ltd; Consulting Agreements: Almirall, Biofrontera Inc, Palvella Therapeutics, Regeneron Pharmaceuticals Inc, Sun Pharmaceutical Industries Ltd, Verrica Pharmaceuticals Inc; Contracted Research: Regeneron Pharmaceuticals Inc; Speakers Bureaus: Almirall, Regeneron Pharmaceuticals Inc, Sun Pharmaceutical Industries Ltd.
  
  Evan Wuthrick, MD
  Senior Member and Vice Chair, Quality and Safety Radiation Oncology
  Moffitt Cancer Center
  Tampa, Florida
  
  No relevant financial relationships to disclose.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  These activities are supported by an educational grant from Regeneron Pharmaceuticals Inc.
  
  Release date: April 2026
  Expiration date: April 2027
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.